A nasal composition of improved stability, its use, and process for production. The nasal composition consists of: xylometazoline hydrochloride (1), 0.01-0.1% w/w ipratropium bromide (2), 0.01-0.1% w/w and pharmaceutical excipients required to form final dosage forms selected from the group consisting of: nasal drops, liquid nasal sprays, or nasal washes. The nasal composition includes the content of purified sea water as a functional, stability-improving excipient, in amounts of 5-25% w/w. The nasal composition has an osmolality within the range 270-820 mOsm/kg, the pH value within the range 3-7, preferably within the range 3-4.2 or 5.8-7.0, and most preferably within the range 3.2-4.2 where it shows improved stability.
